- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04246190
A Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-396
January 30, 2020 updated by: Chong Kun Dang Pharmaceutical
A Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of CKD-501 and D759 in Healthy Adults
The purpose of this study is to evaluate the pharmacokinetics and safety of CKD-396.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Randomized, Open-label, Single-dose, Two-way Crossover Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-396 and Co-administration of CKD-501 and D759 in Healthy Adults
Study Type
Interventional
Enrollment (Anticipated)
26
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Min Soo Park, Ph.D. M.D
- Phone Number: +82-2-2228-0401
- Email: minspark@yuhs.ac
Study Locations
-
-
-
Soeul, Korea, Republic of
- Yonsei University Severance Hospital
-
Contact:
- Min Soo Park, Ph.D. M.D
- Phone Number: +82-2-2228-0401
- Email: minspark@yuhs.ac
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 55 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adult who is 19 ~ 55 years at the time of screening
- Body weight more than 55 kg for male and more than 50kg for female
- BMI more than 18.5 kg/m2 or less than 27.0 kg/m2
- Females must be menopause or surgical infertility
- Males who have consented to the use of appropriate pregnancy contraceptive methods up to 28 days after the last investigational product and not to provide sperm
- Subjects who voluntarily decided to participate and informed consent based upon understanding on the study.
Exclusion Criteria:
- Subjects who have a history of clinically significant hepatic, renal, nervous, immune, respiratory, urinary, digestion, endocrine, hematooncology, cardiovascular systemic disease or psychosis disorder
- Subjects who have diabetic ketoacidoisis, diabetic coma, diabetic precoma, Type 1 diabetes
- Subjects who have genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- Subjects who have a history of gastrointestinal disorders (Crohn's disease, ulcerative colitis, etc.) or surgery (except simple appendectomy or hernia surgery) that may affect the absorption of the drug
- Subjects who have a history of clinically significant hypersensitivity to drugs or additives, including components of the investigational product(lobeglitazone, sitagliptin) and same class drug with thiazolidinediones
- Subjects who have severe infectious disease and severe trauma before and after operation
Subjects who are deemed unsuitable as subjects in the screening test performed within 28 days before the administration of investigational product
- AST, ALT> UNL(Upper Normal Limit)x1.25
- Total bilirubin > UNL(Upper Normal Limit)x1.5
- eGFR (Estimated Glomerular Filtration Rate) <60 mL/min/1.73m2 using the MDRD (Modification of Diet in Renal Disease) formula
- Positive immunologic serological tests (hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test, syphilis test)
- After resting for more than 5 minutes, systolic blood pressure> 150 mmHg or < 90 mmHg, diastolic blood pressure> 100 mmHg or <50 mmHg
- Subjects who have had a history of drug abuse within one year of screening or have tested positive on urine drug screening test
- Pregnant or lactating women
- Subjects who have consistently excessively smoked or consumed caffeine or alcohol (caffeine:> 5 cups / day, alcohol:> 210 g / week, cigarettes:> 10 cigarettes / day) or cannot stop smoking, consuming caffeine and alcohol during hospitalization
Subjects who judged to able to affect in the study or in the subject's safety by the investigator for the following reasons
- Ethical-the-counter (ETC) drugs and herbal medicines within 14 days of the first administration of the investigational drug.
- Over-the-counter (OTC) drugs, including health foods and vitamin preparations, within 7 days of the first dose of the investigational product
- Subjects who have received the investigational product by participating in other clinical trials (including bioequivalence studies) within 180 days before the first dose of the investigational product (For biological agents, this may be based on a longer period of time, considering the half-life)
- Subjects who donated whole blood within 60 days before the first dose of the investigational product or donated component blood donation within 30 days
- Subjects who received a blood transfusion within 60 days before the first dose of the investigational product
- Subjects who were deemed to be inappropriate to participate in the study by the investigator judgment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group 1
|
Reference drug, CKD-501 1T and D759 1T, QD, PO
Reference drug, CKD-396 1T, QD, PO
|
EXPERIMENTAL: Group 2
|
Reference drug, CKD-501 1T and D759 1T, QD, PO
Reference drug, CKD-396 1T, QD, PO
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax of CKD-501, D759 and CKD-396
Time Frame: 0(predose)~48 hours
|
Maximum plasma concentration of CKD-501, D759 and CKD-396
|
0(predose)~48 hours
|
AUClast of CKD-501, D759 and CKD-396
Time Frame: 0(predose)~48 hours
|
Area under the plasma concentration-time curve to last concentration of CKD-501, D759 and CKD-396
|
0(predose)~48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
February 24, 2020
Primary Completion (ANTICIPATED)
April 10, 2020
Study Completion (ANTICIPATED)
July 16, 2020
Study Registration Dates
First Submitted
January 28, 2020
First Submitted That Met QC Criteria
January 28, 2020
First Posted (ACTUAL)
January 29, 2020
Study Record Updates
Last Update Posted (ACTUAL)
February 5, 2020
Last Update Submitted That Met QC Criteria
January 30, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- A65_03BE1921
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type2 Diabetes Mellitus
-
Mathias Ried-LarsenUnknownDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
Hamad Medical CorporationQatar Computing Research Institute (QCRI); Droobi HealthUnknown
-
Andalas UniversityUniversiti Putra MalaysiaCompleted
-
Medstar Health Research InstituteCompletedType2 Diabetes Mellitus
-
Boryung Pharmaceutical Co., LtdRecruiting
-
Georgia Institute of TechnologyNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emory...CompletedType2 Diabetes MellitusUnited States
-
EMSWithdrawnType2 Diabetes Mellitus
-
TheracosCompletedType2 Diabetes MellitusUnited States
-
Chong Kun Dang PharmaceuticalUnknown
Clinical Trials on CKD-501 and D759
-
Chong Kun Dang PharmaceuticalCompletedType 2 Diabetes MellitusKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType 2 DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType2DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalUnknownT2DM (Type 2 Diabetes Mellitus)Korea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType II Diabetes MellitusKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedDiabetes Mellitus, Type 2Korea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Chong Kun Dang PharmaceuticalCompletedType II Diabetes MellitusKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompletedType 2 DiabetesKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted